<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pak J Med Sci</journal-id><journal-id journal-id-type="iso-abbrev">Pak J Med Sci</journal-id><journal-id journal-id-type="publisher-id">PJMS</journal-id><journal-title-group><journal-title>Pakistan Journal of Medical Sciences</journal-title></journal-title-group><issn pub-type="ppub">1682-024X</issn><issn pub-type="epub">1681-715X</issn><publisher><publisher-name>Professional Medical Publicaitons</publisher-name><publisher-loc>Karachi, Pakistan</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25878619</article-id><article-id pub-id-type="pmc">4386162</article-id><article-id pub-id-type="doi">10.12669/pjms.311.6302</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Effects of glutamine and valsartan on the brain natriuretic peptide and N-terminal pro-B-type natriuretic peptide of patients with chronic heart failure</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Shao</surname><given-names>Mingliang</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Congxin</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Zhen</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Hui</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Feng</surname><given-names>Qifan</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Dr. Mingliang Shao, Department of Cardiology, Renmin Hospital of Wuhan University, Cardiovascular Research Institute of Wuhan University, Wuhan, People&#x02019;s Republic of China.</aff><aff id="aff2"><label>2</label>Dr. Congxin Huang, Department of Cardiology, Renmin Hospital of Wuhan University, Cardiovascular Research Institute of Wuhan University, Wuhan, People&#x02019;s Republic of China.</aff><aff id="aff3"><label>3</label>Dr. Zhen Li, Department of Cardiology, Renmin Hospital of Xuancheng City, Xuancheng, People&#x02019;s Republic of China.</aff><aff id="aff4"><label>4</label>Dr. Hui Yang, Department of Cardiology, Renmin Hospital of Xuancheng City, Xuancheng, People&#x02019;s Republic of China.</aff><aff id="aff5"><label>5</label>Dr. Qifan Feng, Department of Cardiology, Renmin Hospital of Xuancheng City, Xuancheng, People&#x02019;s Republic of China.</aff><author-notes><corresp id="cor">Correspondence: Congxin Huang, Department of Cardiology, Renmin Hospital of Wuhan University, Cardiovascular Research Institute of Wuhan University, Wuhan, People&#x02019;s Republic of China. E-mail: huangcxdc@163.com</corresp></author-notes><pub-date pub-type="ppub"><season>Jan-Feb</season><year>2015</year></pub-date><volume>31</volume><issue>1</issue><fpage>82</fpage><lpage>86</lpage><history><date date-type="received"><day>19</day><month>8</month><year>2014</year></date><date date-type="rev-recd"><day>18</day><month>9</month><year>2014</year></date><date date-type="accepted"><day>3</day><month>10</month><year>2014</year></date></history><permissions><license><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">http://creativecommons.org/licenses/by/3.0/</ext-link>) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Objective:</title><p>To analyze the effects of glutamine and valsartan on the brain natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) of patients with chronic heart failure (CHF).</p></sec><sec><title>Methods:</title><p>A total of 140 CHF patients were divided into a treatment group and a control group by random drawing, and were subjected to standard anti-heart failure treatment and administered with valsartan. Besides, the treatment group was also intravenously transfused glutamine. The&#x000a0;treatment lasted eight weeks.</p></sec><sec><title>Results:</title><p> The overall efficacy of treatment group and control group were 98.6% and 90.0% respectively, with a statistically significant difference (P&#x0003c;0.05). The two groups had significantly increased left ventricular ejection fractions as well as significantly decreased left ventricular end-diastolic volumes and left ventricular end-diastolic dimensions after treatments (P&#x0003c;0.05) compared with those before. There were also inter-group differences between these values (P&#x0003c;0.05). After treatment, the levels of BNP, NT-proBNP and CD8<sup>+</sup> in both groups significantly decreased (P&#x0003c;0.05), whereas those of CD4<sup>+</sup> significantly increased (P&#x0003c;0.05). The two groups also had significantly different values (P&#x0003c;0.05).</p></sec><sec><title>Conclusion:</title><p> Glutamine in combination with valsartan enhanced the therapeutic effects by improving cardiac function, which may be associated with decreased expressions of BNP and NT-proBNP and beneficial effects of glutamine on immune function.</p></sec></abstract><kwd-group><title>Key Words</title><kwd>Glutamine</kwd><kwd>Valsartan</kwd><kwd>Chronic heart failure</kwd><kwd>Brain natriuretic peptide</kwd><kwd>N-terminal pro-B-type natriuretic peptide</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>Chronic heart failure (CHF), which is a clinically common and complex syndrome, has poor prognosis for being the ending of a variety of organic heart diseases.<sup><xref rid="B1" ref-type="bibr">1</xref></sup><sup>,</sup><sup><xref rid="B2" ref-type="bibr">2</xref></sup> Currently, CHF has become one of the severe diseases endangering human health with population aging and has thus attracted global attention. As a natriuretic endogenous peptide neurohormone, brain natriuretic peptide (BNP) is mainly secreted by ventricular myocytes, the synthesis of which is closely related with ventricular afterload and wall tension.<sup><xref rid="B3" ref-type="bibr">3</xref></sup><sup>,</sup><sup><xref rid="B4" ref-type="bibr">4</xref></sup> Besides, N-terminal pro-B-type natriuretic peptide (NT-proBNP) contains 108 amino acids after truncating 26 of them at the N-terminal.<sup><xref rid="B5" ref-type="bibr">5</xref></sup><sup>,</sup><sup><xref rid="B6" ref-type="bibr">6</xref></sup></p><p>In human body, BNP is active and decomposes rapidly, but the inactive NT-proBNP remains stable and thus allows easy detection.<sup><xref rid="B7" ref-type="bibr">7</xref></sup> It is now well-established that over-activations of the renin-angiotensin-aldosterone system (RAAS) and the sympathetic nervous system dominantly control the vicious circle of cardiac remodeling and the deterioration of heart function.<sup><xref rid="B8" ref-type="bibr">8</xref></sup> Accordingly, it is of great significance to inhibit the over-activation and vicious circle of neurohumor, and to reverse ventricular remodeling.<sup><xref rid="B9" ref-type="bibr">9</xref></sup> Up to now, angiotensin II receptor blockers (ARBs) are drugs that specifically block Ang II receptors, effectively inhibit Ang II or aldosterone escape, and provide clinical benefits for heart failure patients. Of all ARBs, valsartan has been widely used to treat heart failure.<sup><xref rid="B10" ref-type="bibr">10</xref></sup></p><p>On the other hand, glutamine, a main immune nutrient, provides nitrogen source for the synthesis of amino acids, proteins and nucleic acids. Upon severe wasting diseases such as trauma, heart failure, major surgery and cancer, human body begins to require a large amount of glutamine that, if not supplemented in time, will give rise to various diseases when exhausted.<sup><xref rid="B11" ref-type="bibr">11</xref></sup><sup>,</sup><sup><xref rid="B12" ref-type="bibr">12</xref></sup> Therefore, we herein analyzed the influences of glutamine and valsartan on the BNP and NT-proBNP of CHF patients.</p></sec><sec sec-type="methods"><title>METHODS</title><p>
<bold><italic>Subjects: </italic></bold>A total of 140 CHF patients enrolled in our hospital from September 2010 to January 2014 were selected in this study.</p><p>
<bold><italic>Inclusion criteria:</italic></bold> The patients conforming to the diagnostic standards for CHF; the patients suffering from history or clinical manifestations of congestive heart failure for three months; the patients who had New York Heart Association (NYHA) Class III-IV; the patients with written consent.</p><p>
<bold><italic>Exclusion criteria:</italic></bold> The patients with hepatic and renal insufficiency or myocardial infarction within three months; the patients who had received or were planning to receive heart transplantation; the patients who had stroke within three months; the patients having thyroid disease, blood disorders, endocrine disorders, or connective tissue disease. There were 77 males and 63 females who were aged 41-79 years old (average: 66.44 &#x000b1; 13.73). NYHA classification: 80 cases of Class II, 30 cases of Class III, and 30 cases of Class IV; Disease type: 76 cases of coronary artery disease, 34 cases of dilated cardiomyopathy, 18 cases of hypertensive heart disease, and 12 cases of rheumatic heart disease. They were then divided into a treatment group and a control group by random drawing (n=70), and their basic data such as gender, age, NYHA classification and disease type were similar (P&#x0003e;0.05).</p><p>
<bold><italic>Treatment methods:</italic></bold>
</p><p>
<bold><italic>Control group:</italic></bold> This group was subjected to standard anti-heart failure treatment with ARBs, Digitalis and diuretics (capoten, hydrochlorothiazide and digoxin: 25 mg each, qd), and was administered valsartan (Jiangsu Kanion Pharmaceutical Co., Ltd., National Medicine Permit No. H20090262, 80 mg, qd) simultaneously for eight consecutive weeks.</p><p>
<bold><italic>Treatment group:</italic></bold> In addition to the drugs mentioned above, this group was also intravenously administered glutamine (Sino-Swed Pharmaceutical Co., Ltd., National Medicine Permit No. H20053409, 0.5 mg/kg) by a micro-infusion syringe pump at the speed of 4-5 ml/h for eight consecutive weeks, once a week.</p><p>
<bold><italic>Observation indices: </italic></bold>Detection of BNP and NT-proBNP: Blood (3 ml) was intravenously collected, added into an EP tube containing EDTA-Na<sub>2</sub>, and centrifuged at 3000 rpm for 10 min to separate the plasma. The levels of BNP and NT-proBNP were detected by the enzyme linked immunoassay with a quick bedside testing instrument (Bosch, USA).</p><p>
<bold><italic>Detection of cardiac function:</italic></bold> Left ventricular end-systolic dimension (LVESD), left ventricular end-diastolic dimension (LVEDD) and left ventricular ejection fraction (LVEF) were detected before and after treatment by an experienced sonographer with a Vivid 7 color Doppler ultrasonography (GE, USA).</p><p>
<bold><italic>Evaluation on therapeutic effects:</italic></bold> Markedly effective: Basically controlled clinical symptoms and recovery of over two NYHA classes; effective: gradually controlled clinical symptoms and recovery of one NYHA class; ineffective: uncontrolled clinical symptoms and recovery of less than one NYHA class or even deterioration.</p><p>
<bold><italic>Detection of T-lymphocyte subsets:</italic></bold> Plasma BNP was collected and measured with a kit purchased from Biosino Bio-Technology &#x00026; Science Inc. (China), with the levels of CD4<sup>+</sup> and CD8<sup>+</sup> as the main indices.</p><p>
<bold><italic>Statistical analysis: </italic></bold>The data were analyzed by SPSS 18.0. The numerical data were expressed as (mean &#x000b1; standard deviation) and compared by independent samples t-test and paired t test, and the categorical data were expressed as absolute number or percentage and compared with the Chi-square test. P&#x0003c;0.05 was considered statistically significant.</p></sec><sec sec-type="results"><title>RESULTS</title><p>
<bold><italic>Changes in levels of BNP and NT-proBNP: </italic></bold>After treatment, the levels of BNP and NT-proBNP decreased significantly compared with those before (P&#x0003c;0.05), and the treatment group had significantly lower values than the control group did (P&#x0003c;0.05) (<xref ref-type="table" rid="T1">Table-I</xref>).</p><p>
<bold><italic>Changes in cardiac function indices: </italic></bold>The two groups had significantly increased LVEFs as well as significantly decreased LVEDVs and LVEDDs after treatments (P&#x0003c;0.05) compared with those before. Moreover, there were also inter-group differences between these values (P&#x0003c;0.05) (<xref ref-type="table" rid="T2">Table-II</xref>).</p><p>
<bold><italic>Overall therapeutic effects: </italic></bold>The overall effective rates of the treatment group and the control group were 98.6% and 90.0% respectively, with a statistically significant difference (P&#x0003c;0.05) (<xref ref-type="table" rid="T3">Table-III</xref>).</p><p>
<bold><italic>Changes in T-lymphocyte subsets: </italic></bold>After treatment, the levels of CD8<sup>+</sup> in both groups significantly decreased (P&#x0003c;0.05), whereas those of CD4<sup>+</sup> significantly increased (P&#x0003c;0.05). Meanwhile, the two groups also had significantly different values (P&#x0003c;0.05) (<xref ref-type="table" rid="T4">Table-IV</xref>).</p></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>CHF, as the end stage of heart diseases originating from various reasons other than a simple hemodynamic disorder, involves many neurohormonal factors that keep worsening this disease.<sup><xref rid="B13" ref-type="bibr">13</xref></sup> Traditionally; CHF is treated targeting hemodynamic disorders, which mitigates symptoms by being heart-strengthening, diuretic and blood vessel-dilating. However, this protocol fails to stop the development of CHF or to raise the survival rate.<sup><xref rid="B14" ref-type="bibr">14</xref></sup> The onset and development of heart failure stem from ventricular remodeling on which the activation of neuroendocrine exerts adverse regulating effects. Particularly, long-term over-activation of RAAS predominantly participates in cardiac remodeling and progressive deterioration of CHF.<sup><xref rid="B15" ref-type="bibr">15</xref></sup> As a specific Ang II receptor-blocking agent; valsartan can postpone the development of cardiovascular disease by effectively inhibiting Ang II or aldosterone escape, with the maximum effective rate of only about 90% though.<sup><xref rid="B16" ref-type="bibr">16</xref></sup></p><p>On the other hand, glutamine is crucial for the metabolism and synthesis of nucleic acids and mainly energizes the metabolic activities of intestinal mucosal cells, so supplementing exogenous glutamine has evident protective effects on the intestinal mucosal barrier.<sup><xref rid="B17" ref-type="bibr">17</xref></sup> In the meantime, it is able to stimulate human body to produce glucagon and to boost the intestinal immune function. In this study, the overall effective rates of the treatment group and the control group were 98.6% and 90.0% respectively, with a statistically significant difference (P&#x0003c;0.05). It&#x000a0;has been reported that glutamine can enhance anti-oxidative capacity, promote intestinal tract movement, improve state of nutrition, and thus benefit the recovery of cardiac function.<sup><xref rid="B18" ref-type="bibr">18</xref></sup> Besides, glutamine maintains the integrity of intestinal mucosa, protects the structure and function of intestinal mucosa, prevents endotoxin from entering the blood circulation, and decreases the expressions of inflammatory cytokines and endotoxin, thus reducing the risk of multi-system organ damage.</p><p>The onset and development of CHF involve activation of the sympathetic nervous system and enhanced synthesis and release of BNP from the dilated atrium and ventricle. When over-activated, BNP can dilate the blood vessels and facilitate the natriuresis of CHF patients by regulating the specific receptors of the kidney and vascular smooth muscle.<xref rid="B19" ref-type="bibr">19</xref> Upon severe heart failure, however, this beneficial effect is compensated by vasoactive substance-induced powerful vasoconstriction and sodium retention, thereby leading to poor diagnosis.</p><p>It is now well-known that CHF results in ventricular remodeling by elevating cardiac load. As a result, more NT-proBNP is released because of increased wall tension. Actually, NT-proBNP is not released from necrotic cardiac muscle. Instead, it mainly originates from the survival cardiac muscle under augmented local tension. Additionally, increase in the degree of coronary artery stenosis, which is associated with the increase in involved blood vessels, is able to alarm the degree of CHF.<sup><xref rid="B20" ref-type="bibr">20</xref></sup> In this case, abundant glutamine supplies intestinal mucosal cells with necessary energy and raw materials, reduces the formation of cell membrane lipid peroxides, and thus minimizes the damage to cardiac function. In general, it contributes to the release of some hormones, elevates the activity of intestinal glutaminase, stimulates the pancreas and choleresis, resists the oxidative injury of oxygen free radicals to biomembrane, and increases the survival rate of cells. The two groups had significantly increased LVEFs as well as significantly decreased LVEDVs and LVEDDs after treatments (P&#x0003c;0.05) compared with those before. In addition, there were also inter-group differences between these values (P&#x0003c;0.05).</p><p>CHF patients are prone to body function decline and immune afunction that may induce vicious circle by leading to intestinal hypoperfusion and translocation of normal flora into blood. Under this circumstance, glutamine supplementation improves gastrointestinal functions by enhancing immune function and by boosting nutritional status. Furthermore, supplementation of exogenous glutamine can alleviate vigorous decomposition and metabolism, circumvent its deficiency under stress, facilitate a variety of synthesis and metabolism, and exert immune-enhancing effects.<xref rid="B15" ref-type="bibr">15</xref> In this study, the levels of CD8<sup>+</sup> in both groups significantly decreased after treatment (P&#x0003c;0.05), whereas those of CD4<sup>+</sup> significantly increased (P&#x0003c;0.05). The two groups also had significantly different values (P&#x0003c;0.05).</p><table-wrap id="T1" position="float"><label>Table-I</label><caption><p>Changes in levels of BNP and NT-proBNP (x &#x000b1; s).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" rowspan="2" colspan="1">
<bold>Group</bold>
</th><th align="center" valign="middle" rowspan="2" colspan="1">
<bold>Case number (n)</bold>
</th><th align="center" valign="middle" colspan="2" rowspan="1">
<bold>BNP (ng/L)</bold>
<hr/>
</th><th align="center" valign="middle" colspan="2" rowspan="1">
<bold>NT-proBNP (fmol/ml)</bold>
<hr/>
</th></tr><tr><th align="center" valign="middle" rowspan="1" colspan="1">
<bold>Before</bold>
</th><th align="center" valign="middle" rowspan="1" colspan="1">
<bold>After</bold>
</th><th align="center" valign="middle" rowspan="1" colspan="1">
<bold>Before</bold>
</th><th align="center" valign="middle" rowspan="1" colspan="1">
<bold>After</bold>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Treatment group</td><td align="center" rowspan="1" colspan="1">70</td><td align="center" rowspan="1" colspan="1">298.98&#x000b1;20.83</td><td align="center" rowspan="1" colspan="1">45.93&#x000b1;12.17</td><td align="center" rowspan="1" colspan="1">4.56&#x000b1;0.78</td><td align="center" rowspan="1" colspan="1">2.61&#x000b1;0.45</td></tr><tr><td align="left" rowspan="1" colspan="1">Control group</td><td align="center" rowspan="1" colspan="1">70</td><td align="center" rowspan="1" colspan="1">300.32&#x000b1;21.62</td><td align="center" rowspan="1" colspan="1">98.37&#x000b1;13.87</td><td align="center" rowspan="1" colspan="1">4.59&#x000b1;0.67</td><td align="center" rowspan="1" colspan="1">3.44&#x000b1;0.67</td></tr><tr><td align="left" rowspan="1" colspan="1">t</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.287</td><td align="center" rowspan="1" colspan="1">7.984</td><td align="center" rowspan="1" colspan="1">0.387</td><td align="center" rowspan="1" colspan="1">9.331</td></tr><tr><td align="left" rowspan="1" colspan="1">P</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x0003c;0.05</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.05</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.05</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.05</td></tr></tbody></table></table-wrap><table-wrap id="T2" position="float"><label>Table-II</label><caption><p>Changes in cardiac function indices (x &#x000b1; s</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="center" valign="middle" rowspan="2" colspan="1">
<bold>Group</bold>
</td><td align="center" valign="middle" rowspan="2" colspan="1">
<bold>Case number (n)</bold>
</td><td align="center" valign="middle" colspan="2" rowspan="1">
<bold>LVEF (%)</bold>
<hr/>
</td><td align="center" valign="middle" colspan="2" rowspan="1">
<bold>LVEDV (mm)</bold>
<hr/>
</td><td align="center" valign="middle" colspan="2" rowspan="1">
<bold>LVEDD (mm)</bold>
<hr/>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Before</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>After</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Before</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>After</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Before</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>After</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Treatment group</td><td align="center" rowspan="1" colspan="1">70</td><td align="left" rowspan="1" colspan="1">35.56&#x000b1;8.24</td><td align="left" rowspan="1" colspan="1">45.87&#x000b1;4.91</td><td align="left" rowspan="1" colspan="1">249.64&#x000b1;45.95</td><td align="left" rowspan="1" colspan="1">165.09&#x000b1;32.98</td><td align="left" rowspan="1" colspan="1">93.65&#x000b1;15.96</td><td align="left" rowspan="1" colspan="1">61.67&#x000b1;16.33</td></tr><tr><td align="left" rowspan="1" colspan="1">Control group</td><td align="center" rowspan="1" colspan="1">70</td><td align="left" rowspan="1" colspan="1">35.56&#x000b1;8.47</td><td align="left" rowspan="1" colspan="1">40.98&#x000b1;5.33</td><td align="left" rowspan="1" colspan="1">252.52&#x000b1;65.87</td><td align="left" rowspan="1" colspan="1">206.87&#x000b1;40.83</td><td align="left" rowspan="1" colspan="1">93.78&#x000b1;16.09</td><td align="left" rowspan="1" colspan="1">74.96&#x000b1;16.00</td></tr><tr><td align="left" rowspan="1" colspan="1">t</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.000</td><td align="left" rowspan="1" colspan="1">4.983</td><td align="left" rowspan="1" colspan="1">0.329</td><td align="left" rowspan="1" colspan="1">7.948</td><td align="left" rowspan="1" colspan="1">0.034</td><td align="left" rowspan="1" colspan="1">9.223</td></tr><tr><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.05</td><td align="left" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.05</td><td align="left" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.05</td></tr></tbody></table></table-wrap><table-wrap id="T3" position="float"><label>Table-III</label><caption><p>Overall therapeutic effects (n).</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Group</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Case number (n)</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Markedly effective</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Effective</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Ineffective</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Overall effective rate</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Treatment group</td><td align="center" rowspan="1" colspan="1">70</td><td align="center" rowspan="1" colspan="1">60</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">98.6%</td></tr><tr><td align="left" rowspan="1" colspan="1">Control group</td><td align="center" rowspan="1" colspan="1">70</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">90.0%</td></tr><tr><td align="left" rowspan="1" colspan="1"> &#x003c7;&#x000b2;</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">5.442</td></tr><tr><td align="left" rowspan="1" colspan="1">P</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x0003c;0.05</td></tr></tbody></table></table-wrap><table-wrap id="T4" position="float"><label>Table-IV</label><caption><p>Changes in T-lymphocyte subsets (%, x &#x000b1; s).</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="center" valign="middle" rowspan="2" colspan="1">
<bold>Group</bold>
</td><td align="center" valign="middle" rowspan="2" colspan="1">
<bold>Case number (n)</bold>
</td><td align="center" valign="middle" colspan="2" rowspan="1">
<bold>CD4</bold>
<sup>+</sup>
<hr/>
</td><td align="center" valign="middle" colspan="2" rowspan="1">
<bold>CD8</bold>
<sup>+</sup>
<hr/>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Before</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>After</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Before</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>After</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Treatment group</td><td align="center" rowspan="1" colspan="1">70</td><td align="left" rowspan="1" colspan="1">35.93&#x000b1;2.98</td><td align="left" rowspan="1" colspan="1">50.98&#x000b1;3.18</td><td align="left" rowspan="1" colspan="1">31.37&#x000b1;4.71</td><td align="left" rowspan="1" colspan="1">19.76&#x000b1;4.78</td></tr><tr><td align="left" rowspan="1" colspan="1">Control group</td><td align="center" rowspan="1" colspan="1">70</td><td align="left" rowspan="1" colspan="1">36.00&#x000b1;3.67</td><td align="left" rowspan="1" colspan="1">45.39&#x000b1;3.76</td><td align="left" rowspan="1" colspan="1">31.78&#x000b1;4.26</td><td align="left" rowspan="1" colspan="1">25.96&#x000b1;4.10</td></tr><tr><td align="left" rowspan="1" colspan="1">t</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.287</td><td align="left" rowspan="1" colspan="1">5.898</td><td align="left" rowspan="1" colspan="1">0.438</td><td align="left" rowspan="1" colspan="1">7.001</td></tr><tr><td align="left" rowspan="1" colspan="1">P</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c;0.05</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.05</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.05</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.05</td></tr></tbody></table></table-wrap><p>In summary, valsartan, when combined with glutamine, has satisfactory therapeutic effects on CHF patients by being conducive to cardiac function, which is related with the decreased expressions of BNP and NT-proBNP as well as the beneficial effects of glutamine on immune function.</p></sec><sec><title>Authors Contribution:</title><p>
<bold>MLS &#x00026; CXH </bold>conceived, designed and did statistical analysis &#x00026; editing of manuscript.</p><p>
<bold>ZL</bold>
<bold>, </bold>
<bold>HY</bold>
<bold>&#x00026;</bold>
<bold>QFF</bold> did data collection and manuscript writing.</p><p>
<bold>CXH</bold> did review and final approval of manuscript.</p><p>
<bold>CXH</bold> takes the responsibility and is accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.</p></sec></body><back><sec><title/><p>
<bold><italic>Conflicts of interest: </italic></bold>All the authors declare no conflicts of interest.</p></sec><ref-list><title>References</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rold&#x000e1;n</surname><given-names>V</given-names></name><name><surname>V&#x000ed;lchez</surname><given-names>JA</given-names></name><name><surname>Manzano-Fern&#x000e1;ndez</surname><given-names>S</given-names></name><name><surname>Jover</surname><given-names>E</given-names></name><name><surname>G&#x000e1;lvez</surname><given-names>J</given-names></name><name><surname>Puche</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Usefulness of N-terminal pro-B-type natriuretic Peptide levels for stroke risk prediction in anticoagulated patients with atrial fibrillation</article-title><source> Stroke</source><year>2014</year><volume>45</volume><issue>3</issue><fpage>696</fpage><lpage>701</lpage><comment>doi:&#x000a0;10.1161/STROKEAHA.113.003338</comment><pub-id pub-id-type="pmid">24519407</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nikonova</surname><given-names>ES</given-names></name><name><surname>Suslova</surname><given-names>TE</given-names></name><name><surname>Riabov</surname><given-names>VV</given-names></name><name><surname>Shurupov</surname><given-names>VS</given-names></name></person-group><article-title>The cerebral sodium uretric peptide (see text symbol) patients with chronic cardiac insufficiency under decreased and preserved ejection fraction</article-title><source> Klin Lab Diagn</source><year>2013</year><issue>8</issue><fpage>21</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">24340744</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rotovnik</surname><given-names>KN</given-names></name><name><surname>Kompan</surname><given-names>L</given-names></name><name><surname>Soeters</surname><given-names>P</given-names></name><name><surname>Oblak</surname><given-names>I</given-names></name><name><surname>Mlakar</surname><given-names>Mastnak D</given-names></name><name><surname>Mo&#x0017e;ina</surname><given-names>B</given-names></name><etal/></person-group><article-title>Oral glutamine supplementation du6ng preoperative radiochemotherapy in patients with rectal cancer: a randomised double blinded, placebo controlled pilot study</article-title><source> Clin Nutr</source><year>2011</year><volume>30</volume><issue>5</issue><fpage>567</fpage><lpage>570</lpage><comment>doi: 10.1016/j.clnu.2011.06.003</comment><pub-id pub-id-type="pmid">21733605</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narin</surname><given-names>N</given-names></name><name><surname>Hekimoglu</surname><given-names>B</given-names></name><name><surname>Baykan</surname><given-names>A</given-names></name><name><surname>Ozyurt</surname><given-names>A</given-names></name><name><surname>Zararsiz</surname><given-names>G</given-names></name><name><surname>Sezer</surname><given-names>S</given-names></name><etal/></person-group><article-title>The role of N-terminal proBNP in the clinic scoring of heart failure due to dilated cardiomyopathy in children</article-title><source> Clin Lab</source><year>2014</year><volume>60</volume><issue>4</issue><fpage>563</fpage><lpage>570</lpage><pub-id pub-id-type="pmid">24779290</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taskapan</surname><given-names>H</given-names></name><name><surname>Taskapan</surname><given-names>MC</given-names></name><name><surname>Orman</surname><given-names>I</given-names></name><name><surname>Ulutas</surname><given-names>O</given-names></name><name><surname>Yigit</surname><given-names>A</given-names></name><name><surname>Ozyalin</surname><given-names>F</given-names></name><etal/></person-group><article-title>NGAL and NT-proBNP levels in diabetic patients with macroproteinuria</article-title><source> Ren Fail</source><year>2013</year><volume>35</volume><issue>9</issue><fpage>1273</fpage><lpage>1277</lpage><pub-id pub-id-type="pmid">23964619</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wernerman</surname><given-names>J</given-names></name><name><surname>Kirketeig</surname><given-names>T</given-names></name><name><surname>Andersson</surname><given-names>B</given-names></name><name><surname>Berthelson</surname><given-names>H</given-names></name><name><surname>Ersson</surname><given-names>A</given-names></name><name><surname>Friberg</surname><given-names>H</given-names></name><etal/></person-group><article-title>Scandinavian glutamine trial: a pragmatic multi-centre randomised clinical trial of intensive care unit patients</article-title><source> Acta Anaesthesiol Scand</source><year>2011</year><volume>55</volume><issue>7</issue><fpage>812</fpage><lpage>814</lpage><pub-id pub-id-type="pmid">21658010</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>CL</given-names></name><name><surname>Sun</surname><given-names>R</given-names></name><name><surname>Qiao</surname><given-names>XJ</given-names></name><name><surname>Xu</surname><given-names>CC</given-names></name><name><surname>Shang</surname><given-names>XY</given-names></name><name><surname>Niu</surname><given-names>WN</given-names></name></person-group><article-title>Protective effect of glutamine on intestinal injury and bacterial community in rats exposed to hypobaric hypoxia environment</article-title><source> World J Gastroenterol</source><year>2014</year><volume>20</volume><issue>16</issue><fpage>4662</fpage><lpage>4674</lpage><comment>doi: 10.3748/wjg.v20.i16.4662</comment><pub-id pub-id-type="pmid">24782618</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Badole</surname><given-names>SL</given-names></name><name><surname>Jangam</surname><given-names>GB</given-names></name><name><surname>Chaudhari</surname><given-names>SM</given-names></name><name><surname>Ghule</surname><given-names>AE</given-names></name><name><surname>Zanwar</surname><given-names>AA</given-names></name></person-group><article-title>L-glutamine supplementation prevents the development of experimental diabetic cardiomyopathy in streptozotocin-nicotinamide induced diabetic rats</article-title><source> PLoS One</source><year>2014</year><volume>9</volume><issue>3</issue><lpage>e92697</lpage><comment>doi:&#x000a0;10.1371/journal.pone.0092697</comment></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Badeau</surname><given-names>RM</given-names></name><name><surname>Honka</surname><given-names>MJ</given-names></name><name><surname>Lautam&#x000e4;ki</surname><given-names>R</given-names></name><name><surname>Stewart</surname><given-names>M</given-names></name><name><surname>Kangas</surname><given-names>AJ</given-names></name><name><surname>Soininen</surname><given-names>P</given-names></name><etal/></person-group><article-title>Systemic metabolic markers and myocardial glucose uptake in type 2 diabetic and coronary artery disease patients treated for 16 weeks with rosiglitazone, a PPAR&#x003b3; agonist</article-title><source> Ann Med</source><year>2014</year><volume>46</volume><issue>1</issue><fpage>18</fpage><lpage>23</lpage><comment>doi: 10.3109/07853890.2013.853369</comment><pub-id pub-id-type="pmid">24266715</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qi</surname><given-names>L</given-names></name><name><surname>Qi</surname><given-names>Q</given-names></name><name><surname>Prudente</surname><given-names>S</given-names></name><name><surname>Mendonca</surname><given-names>C</given-names></name><name><surname>Andreozzi</surname><given-names>F</given-names></name><name><surname>di</surname><given-names>Pietro N</given-names></name><etal/></person-group><article-title>Association between a genetic variant related to glutamic acid metabolism and coronary heart disease in individuals with type 2 diabetes</article-title><source> JAMA</source><year>2013</year><volume>310</volume><issue>8</issue><fpage>821</fpage><lpage>828</lpage><comment>doi: 10.1001/jama.2013.276305</comment><pub-id pub-id-type="pmid">23982368</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>A</given-names></name><name><surname>Markowski</surname><given-names>A</given-names></name><name><surname>Momma</surname><given-names>M</given-names></name><name><surname>Seipt</surname><given-names>C</given-names></name><name><surname>Luettig</surname><given-names>B</given-names></name><name><surname>Hadem</surname><given-names>J</given-names></name><etal/></person-group><article-title>Tolerability and efficacy of a low-volume enteral supplement containing key nutrients in the critically ill</article-title><source> Clin Nutr</source><year>2011</year><volume>30</volume><issue>5</issue><fpage>599</fpage><lpage>603</lpage><comment>doi: 10.1016/j.clnu.2011.04.003</comment><pub-id pub-id-type="pmid">21621886</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kidher</surname><given-names>E</given-names></name><name><surname>Harling</surname><given-names>L</given-names></name><name><surname>Ashrafian</surname><given-names>H</given-names></name><name><surname>Naase</surname><given-names>H</given-names></name><name><surname>Francis</surname><given-names>DP</given-names></name><name><surname>Evans</surname><given-names>P</given-names></name><etal/></person-group><article-title>Aortic stiffness as a marker of cardiac function and myocardial strain in patients undergoing aortic valve replacement</article-title><source> J Cardiothorac Surg</source><year>2014</year><volume>9</volume><issue>1</issue><lpage>102</lpage><comment>doi: 10.1186/1749-8090-9-102</comment></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Ling</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>H</given-names></name></person-group><article-title>Prognostic value of brain natriuretic peptide in patients with heart failure and reserved left ventricular systolic function</article-title><source> Exp Ther Med</source><year>2014</year><volume>7</volume><issue>6</issue><fpage>1506</fpage><lpage>1512</lpage><pub-id pub-id-type="pmid">24926333</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Limburg</surname><given-names>PJ</given-names></name><name><surname>Mahoney</surname><given-names>MR</given-names></name><name><surname>Ziegler</surname><given-names>KL</given-names></name><name><surname>Sontag</surname><given-names>SJ</given-names></name><name><surname>Schoen</surname><given-names>RE</given-names></name><name><surname>Benya</surname><given-names>R</given-names></name><etal/></person-group><article-title>Randomized phase II trial of sulindac, atorvastatin, andprebiotic dietary fiber for colorectal cancer chemoprevention</article-title><source> Cancer Prey Res (Phila)</source><year>2011</year><volume>4</volume><issue>2</issue><fpage>259</fpage><lpage>269</lpage><comment>doi:&#x000a0;10.1158/1940-6207.CAPR-10-0215</comment></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Mao</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>SH</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Luo</surname><given-names>QZ</given-names></name><name><surname>Pan</surname><given-names>WQ</given-names></name><etal/></person-group><article-title>Is right ventricular mid-septal pacing superior to apical pacing in patients with high degree atrio-ventricular block and moderately depressed left ventricular function?</article-title><source> J Zhejiang Univ Sci B</source><year>2014</year><volume>15</volume><issue>6</issue><fpage>507</fpage><lpage>514</lpage><comment>doi:&#x000a0;10.1631/jzus.B1400034</comment><pub-id pub-id-type="pmid">24903987</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garc&#x000ed;a-Berrocoso</surname><given-names>T</given-names></name><name><surname>Giralt</surname><given-names>D</given-names></name><name><surname>Bustamante</surname><given-names>A</given-names></name><name><surname>Etgen</surname><given-names>T</given-names></name><name><surname>Jensen</surname><given-names>JK</given-names></name><name><surname>Sharma</surname><given-names>JC</given-names></name><etal/></person-group><article-title>B-type natriuretic peptides and mortality after stroke: a systematic review and meta-analysis</article-title><source> Neurology</source><year>2013</year><volume>81</volume><issue>23</issue><fpage>1976</fpage><lpage>1985</lpage><comment>doi: 10.1212/01.wnl.0000436937.32410.32</comment><pub-id pub-id-type="pmid">24186915</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pufulete</surname><given-names>M</given-names></name><name><surname>Higgins</surname><given-names>JP</given-names></name><name><surname>Rogers</surname><given-names>CA</given-names></name><name><surname>Dreyer</surname><given-names>L</given-names></name><name><surname>Hollingworth</surname><given-names>W</given-names></name><name><surname>Dayer</surname><given-names>M</given-names></name><etal/></person-group><article-title>Protocol for a systematic review and individual participant data meta-analysis of B-type natriuretic peptide-guided therapy for heart failure</article-title><source> Syst Rev</source><year>2014</year><volume>3</volume><issue>1</issue><fpage>41</fpage><lpage>42</lpage><comment>doi:&#x000a0;10.1186/2046-4053-3-41</comment><pub-id pub-id-type="pmid">24886933</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hua</surname><given-names>N</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Phinikaridou</surname><given-names>A</given-names></name><name><surname>Pham</surname><given-names>T</given-names></name><name><surname>Qiao</surname><given-names>Y</given-names></name><name><surname>LaValley</surname><given-names>MP</given-names></name><etal/></person-group><article-title>The influence of pericardial fat upon left ventricular function in obese females: evidence of a site-specific effect</article-title><source> J Cardiovasc Magn Reson</source><year>2014</year><volume>16</volume><issue>1</issue><fpage>37</fpage><lpage>38</lpage><comment>doi: 10.1186/1532-429X-16-37</comment><pub-id pub-id-type="pmid">24884541</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sacchetto</surname><given-names>E</given-names></name><name><surname>Ali</surname><given-names>D</given-names></name><name><surname>Dumontet</surname><given-names>E</given-names></name><name><surname>Le</surname><given-names>Carrer D</given-names></name><name><surname>Orsonneau</surname><given-names>JL</given-names></name><name><surname>Delaroche</surname><given-names>O</given-names></name><etal/></person-group><article-title>[Influence of anticoagulant on the plasma level of fifteen biochemical parameters]</article-title><source> Ann Biol Clin (Paris)</source><year>2014</year><volume>72</volume><issue>3</issue><fpage>337</fpage><lpage>350</lpage><comment>doi: 10.1684/abc.2014.0959</comment><pub-id pub-id-type="pmid">24876145</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>GW</given-names></name><name><surname>Li</surname><given-names>ZM</given-names></name><name><surname>Wang</surname><given-names>LP</given-names></name><name><surname>Ye</surname><given-names>JT</given-names></name><etal/></person-group><article-title>AG-690/11026014, a novel PARP-1 inhibitor, protects cardiomyocytes from AngII-induced hypertrophy</article-title><source> Mol Cell Endocrinol</source><year>2014</year><volume>392</volume><issue>1-2</issue><fpage>14</fpage><lpage>22</lpage><comment>doi: 10.1016/j.mce.2014.05.010</comment><pub-id pub-id-type="pmid">24859603</pub-id></element-citation></ref></ref-list></back></article>